C8 MediSensors, a US-based diabetes treatment company backed by US-based conglomerate General Electric, has raised $19m.

The funding will help C8 MediSensors launch in Europe. C8 MediSensors said its “leading investors” participated in the round.

C8 MediSensors uses light, in a process called Raman spectroscopy, to allow diabetics to measure glucose in a monitor.

C8 Medisensors secured $24m in its series C funding last year investors including General Electric’s GE Capital financial services division and its GE Healthcare division, which…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?